Alpha Registry
Claim a profile

Company Profile

Public information reviewed
AC Immune SA logo

AC Immune SA

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools.

USNASDAQ: ACIU
Follow
More
Reports & analysisAlpha EvalSave PDFAsk Alpha

Company record

At a glance

Legal name
AC Immune SA
Industry
Biotechnology
Sector
Healthcare
Primary listing
NASDAQ: ACIU
Public sources
1 reviewed
Published leadership records
0
Last reviewed
Sep 5, 2026
View sources

Governance brief

Company Governance Record

Canonical ID
alpha:company:e480b51f-348a-496a-ac6b-2971a4aab349
Published claims
5
Mandate and committee claims
Not asserted
Evidence sources
1
Last reviewed
Sep 5, 2026
Verification
Source reported

Counts describe published records, not completeness. Missing fields remain unknown, not zero.

Record coverage summary

  • identityPublished
  • businessPublished
  • leadershipNot asserted
  • board and committeesNot asserted
  • governanceNot asserted
  • financialsNot asserted
  • workforceNot asserted
  • ownershipNot asserted
  • EvalsNot published
  • market and index contextPublished

Public retrieval: Allowed · Agent retrieval: Allowed · Redistribution: Not granted

What the company does

About

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implic

Top capabilities · Alpha-derived

Derived from the governed company description, operating model, published facts, and source record. These descriptors indicate observed focus areas, not a rating or endorsement.

Assertion
Alpha inference
Publication
Published
Basis
Governed public record

Not enough public evidence to publish derived descriptors.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · canonical_identityAlpha canonical company public projectionSupports Company identity, Published leadership, Entity status boundary. Reviewed Sep 5, 2026.Open source

Stable business record

Identity and status

Ownership and listing state

Public listing published

Ownership not asserted

The canonical public record includes at least one active security listing.

Inspect status source
Legal name
AC Immune SA
Inspect source
Country
US
Inspect source
Sector
Healthcare
Inspect source
Industry
Biotechnology
Inspect source

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 5, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

0 public records

Executive roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no executive team.

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Public professional graph

Leadership network lens

Published affiliations, capability adjacency, and evidence-labelled relationship signals. Private familiarity or influence is not asserted.

Leadership constellation

Unavailable

A public leadership projection is not available in the governed Boardroom source set.

unavailable · 0 evidence records

Leadership movement

Unavailable

The current company record does not publish a leadership-change series.

unavailable · 0 evidence records

Board interlocks

Not asserted

No second company board seat is established for the same published director in this source set.

unavailable · 0 evidence records

Leadership capability coverage

Unavailable

No public capability taxonomy is attached to this company and its published leadership records.

unavailable · 0 evidence records

Evidence concentration

Unavailable

This describes the public record mix and does not score governance quality, influence, or independence.

unavailable · 0 evidence records

Temporal relationship trace

Published affiliations

Unavailable · no published affiliation series is attached to this record.

Capability adjacency

Published areas

    Unavailable · no public capability taxonomy is attached.

    Direct contact, private mutual connections, and relationship pathfinding are not exposed.

    Disclosure boundary

    Governance and independence

    Only current, confirmed leadership roles with public evidence are included in the canonical projection.

    RecordStatusAuthorityEffective

    Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.

    Sources

    Sources and published information

    Alpha canonical company public projection

    Supports Company identity, Published leadership, Entity status boundary.

    Open source
    State
    Published
    Source type
    canonical_identity
    Last reviewed
    Sep 5, 2026